Fulcrum Therapeutics Appoints New CCO and Regulatory Officer
Category: News
Total Views: 20
By : IH Newswire
Updated: 08-19-2024
Fulcrum Therapeutics Enhances Leadership with New Appointments
Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering clinical-stage biopharmaceutical company committed to developing innovative treatments for genetically defined rare diseases, has announced the strategic appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs and Quality Assurance Officer. These appointments are pivotal in advancing the lead drug candidate, losmapimod, towards... Read More
Next Hydrogen Partners with University for Advanced Ammonia Tech
Category: News
Total Views: 19
By : IH Newswire
Updated: 08-19-2024
Next Hydrogen Teams Up with University for Ammonia Production Research
Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a leading designer and manufacturer of electrolyzers, is thrilled to share that it has secured a contract with the University of Minnesota (UMN) to provide its cutting-edge electrolysis technology. This installation will take place at the UMN West Central Research and Outreach Center (WCROC).
The WCROC initiative is backed by the U... Read More
CECO Environmental Schedules Important Investor Conferences
Category: News
Total Views: 20
By : IH Newswire
Updated: 08-19-2024
CECO Environmental Announces Upcoming Investor Conferences
CECO Environmental Corp. (Nasdaq: CECO), a top-tier company committed to environmentally focused solutions, has announced the upcoming investor conferences where its management will present. These conferences represent vital opportunities for the company to communicate its innovative strategies and growth initiatives aimed at protecting both people and the environment.
Conference Details
August 29, 2024 – 15th Annual Midwest ... Read More
Supernus Pharmaceuticals Announces FDA Review for SPN-830 Device
Category: News
Total Views: 23
By : IH Newswire
Updated: 08-19-2024
Supernus Pharmaceuticals Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PDUFA Target Action Date of February 1, 2025
ROCKVILLE, Md. — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company dedicated to the development and commercialization of products for treating central nervous system (CNS) disorders, has reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the new drug application (NDA) for its innov... Read More
InspireSemi Extends Private Placement with Successful Tranche Close
Category: News
Total Views: 21
By : IH Newswire
Updated: 08-19-2024
InspireSemi Extends Private Placement and Closes First Tranche
Vancouver, British Columbia, and Austin, Texas — Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a leading chip design company specializing in high-performance, energy-efficient accelerated computing solutions for demanding applications like High Performance Computing (HPC), AI, and graph analytics, has announced a notable development regarding its financing activities.
The Company has ap... Read More